Clinical trials: S. Aureus Bloodstream Infection
Staphylococcus Aureus Bacteremia, Infective Endocarditis
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
The goal of this prospective interventionist cohort study is to assess the prevalence of infective endocarditis in patients with Staphylococcus aureus bacteremia at low risk of this complication.
- Trial name
- ET-AUREUS (NCT05862025)
- Testing
- Echocardiography evaluation
- Where
- Spain
- Volunteers
- 470 people
- Sponsor
- Puerta de Hierro University Hospital
Nosocomial Infection, Healthcare-associated Infection
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Hypothesis: The use of daptomycin to treat nosocomial or healthcare-associated bacteremia due to methicillin-resistant S. aureus (MRSA) would increase the proportion of patients whose blood cultures are sterilized after 72 hours…
- Trial name
- DAVASAB (NCT01515020)
- Testing
- vancomycin monotherapy, daptomycin monotherapy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Infection
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
Increasing resistance to antibiotic agents has been recognized as a major health problem worldwide that will even aggravate due to the lack of new antimicrobial agents within the next decade [1].
- Trial name
- SABATO (NCT01792804)
- Testing
- Trimethoprim-Sulfamethoxazole, Clindamycin, Linezolid
- Where
- 40 sites in France, Germany and 3 more
- Volunteers
- 215 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
The goal of this study is to investigate if benzylpenicillin is a better treatment option than cloxacillin in patients with penicillin-susceptible Staphylococcus aureus bacteraemia.
- Conditions
- Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia), Staphylococcus (S.) Aureus Infection
- Trial name
- COMeBAC (NCT06726395)
- Testing
- Penicillin G_1200mg, cloxacillin
- Where
- Sweden
- Volunteers
- 420 people
- Sponsor
- Region Skane
Methicillin Susceptible Staphylococcus Aureus Septicemia, Bacteremia
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
The purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible S. aureus.
- Trial name
- DASH (NCT02972983)
- Testing
- Daptomycin
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Bacteremia
Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives
Direct in-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform, two…
- Trial name
- NCT01184339
- Testing
- MicroPhage S. aureus/MSSA/MRSA Blood Culture Test
- Volunteers
- 1,165 people
- Sponsor
- MicroPhage, Inc.
Staphylococcus Aureus Bloodstream Infection
A Phase I Study of XJ101 in Chinese Healthy Subjects
This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria.
- Trial name
- NCT06014736
- Testing
- XJ101 for Injection
- Where
- China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Starmab biologics（Shanghai）Co,.ltd
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
Having bacteria in the blood can be very dangerous. This is called bacteraemia (or bacteremia) or bloodstream infection. It can lead to problems across the whole body, which is what happens in sepsis.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Sepsis Bacterial, Bloodstream Infection
- Trial name
- PET-SAB (NCT05361135)
- Testing
- PET/CT
- Volunteers
- 820 people
- Sponsor
- University College, London
Staphylococcus Aureus Bloodstream Infection
A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults
The purpose of this study is to evaluate the safety and PK of AZD7760 when given as an intravenous (IV) infusion to healthy Japanese adult participants.
- Trial name
- NCT07612813
- Testing
- AZD7760
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Toxic Shock Syndrome Staphylococcal
Phase I STEBVax in Healthy Adults
The main purpose of this study is to test the safety of a new vaccine, STEBVax, which may lead to a useful treatment for toxic shock syndrome.
- Trial name
- NCT00974935
- Testing
- Aluminum hydroxide, STEBVax vaccine
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Linezolid Plus Standard of Care
The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
- Trial name
- LIPS (NCT06958835)
- Testing
- Linezolid 600 mg
- Where
- 12 sites in Switzerland
- Volunteers
- 606 people
- Sponsor
- University Hospital, Basel, Switzerland
Methicillin-resistant Staphylococcus Aureus, Sepsis
Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project
Determine if a cystatin C-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Sepsis, Critical Illness
- Trial name
- NCT02945241
- Testing
- Vancomycin, Cystatin C dosing algorithm, Creatine clearance dosing algorithm
- Volunteers
- 399 people
- Sponsor
- Mayo Clinic
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacteremia
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
In vitro identification of S. aureus,methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)from positive blood culture using MicroPhage's bacteriophage-based diagnostic platform.
- Trial name
- NCT01640886
- Where
- 3 sites in United States
- Volunteers
- 764 people
- Sponsor
- MicroPhage, Inc.
Methicillin Susceptible Staphylococcus Aureus Septicemia
Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia
Background: Despite management improvement in lasts years, S.aureus bacteremia leads to high morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus (MSSA) bacteremia standard treatment was cloxacillin.
- Trial name
- SAFO (NCT03959345)
- Testing
- Combination therapy group, Standard therapy group
- Where
- 17 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Miquel Pujol
Bacterial Infections
Clinical Impact of Rapid AST Directly From Blood Cultures
Bacteremia is defined as pathogenic bacteria presence in blood as evidenced by positive blood cultures. These bacteremia have significant consequences in terms of morbidity and mortality (ref. 1,2,3).
- Trial name
- MHR-BC (NCT03992703)
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events.
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- Clopido-SNAP 2 (NCT06650488)
- Testing
- Clopidogrel, Aspirin
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Endocarditis, Bacterial, Infective Endocarditis
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of…
- Trial name
- HDSAB (NCT00695903)
- Testing
- daptomycin, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis
- Trial name
- CERT (NCT04886284)
- Testing
- Ertapenem
- Where
- 7 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Bacteremia, Staphylococcus Aureus
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to…
- Conditions
- Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph
- Trial name
- diSArm (NCT05184764)
- Testing
- AP-SA02
- Where
- 28 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Armata Pharmaceuticals, Inc.